Several conglomerates from the pharmaceutical industry announced on Monday that they would be recalling Cory Booker, after finding the candidate was malfunctioning.
“To be clear: This recall isn’t because the product is dangerous,” said Craig Landau, CEO of Purdue Pharma. “It’s actually completely harmless. It’s just that it doesn’t do anything. We developed this candidate with high hopes, but its results have been so ineffective lately that we figured we’d save the $400,000 in maintenance fees and just let the patent expire. We do feel a little bad, because until 2017, he really had been bringing us a lot of value, but we’re just going to have to knuckle down and create a better candidate for next time.”